Literature DB >> 11207249

Cumulative inhibition of NK cells and T cells resulting from engagement of multiple inhibitory Ly49 receptors.

T Hanke1, D H Raulet.   

Abstract

Inhibitory receptors specific for MHC class I molecules are expressed on partially overlapping subpopulations of NK cells and memory T cells. A central question pertinent to NK cell development and function is how the combinatorial expression of different receptors with distinct class I specificities affects functional recognition. We therefore studied the quantitative effects resulting from class I engagement of multiple inhibitory Ly49 receptors. We used a transgenic mouse model in which all NK cells and T cells express two different Ly49 receptors with shared class I specificity. Comparisons of cells from these mice with cells from single transgenic mice and wild-type mice revealed that Ly49 receptors cumulatively inhibit lymphocyte effector functions. Multiple Ly49 interactions also had a cumulative impact on NK cell development. The findings suggest that the interactions of inhibitory receptors with class I are interpreted quantitatively rather than as on/off switches. They have intriguing implications concerning NK cell tolerance and reactivity toward cells with extinguished expression of a limited number of class I molecules.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207249     DOI: 10.4049/jimmunol.166.5.3002

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Receptor/ligand avidity determines the capacity of Ly49 inhibitory receptors to interfere with T-cell receptor-mediated activation.

Authors:  Anick Chalifour; Joanne Roger; Suzanne Lemieux; Pascale Duplay
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 2.  Innate immune control of HIV.

Authors:  Mary Carrington; Galit Alter
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules.

Authors:  Nadine C Fernandez; Emmanuel Treiner; Russell E Vance; Amanda M Jamieson; Suzanne Lemieux; David H Raulet
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

Review 4.  Cis interactions of immunoreceptors with MHC and non-MHC ligands.

Authors:  Werner Held; Roy A Mariuzza
Journal:  Nat Rev Immunol       Date:  2008-02-29       Impact factor: 53.106

5.  IL-2 mediates NK cell proliferation but not hyperactivity.

Authors:  Richa Sharma; Asmita Das
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

6.  NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model.

Authors:  Nathalie T Joncker; Nadine C Fernandez; Emmanuel Treiner; Eric Vivier; David H Raulet
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 7.  Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells.

Authors:  Nathalie T Joncker; David H Raulet
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

8.  Expression of natural killer receptor alleles at different Ly49 loci occurs independently and is regulated by major histocompatibility complex class I molecules.

Authors:  D M Tanamachi; T Hanke; H Takizawa; A M Jamieson; D R Raulet
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

9.  Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice.

Authors:  Seung-Hwan Lee; Ahmed Zafer; Yves de Repentigny; Rashmi Kothary; Michel L Tremblay; Philippe Gros; Pascale Duplay; John R Webb; Silvia M Vidal
Journal:  J Exp Med       Date:  2003-02-17       Impact factor: 14.307

10.  Natural killer cell inhibitory receptor expression in humans and mice: a closer look.

Authors:  Michal Sternberg-Simon; Petter Brodin; Yishai Pickman; Björn Onfelt; Klas Kärre; Karl-Johan Malmberg; Petter Höglund; Ramit Mehr
Journal:  Front Immunol       Date:  2013-03-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.